A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


May 28, 2010

Antiretroviral Treatment Cuts HIV Transmission Rate by 92 Percent

Heterosexual HIV-positive people who are taking antiretroviral (ARV) therapy were 92 percent less likely to pass on the virus to their HIV-negative sex partners, according to a study published online May 27 in The Lancet.

A number of studies over the past decade have suggested that HIV transmission is cut dramatically in mixed HIV status couples—called serodiscordance—if the partner with HIV is taking ARVs and has an undetectable viral load.

These data were used by the Swiss Federal Commission for HIV/AIDS in its hotly debated February 2008 declaration concluding, “an HIV-infected person on antiretroviral therapy with completely suppressed viremia (‘effective ART’) is not sexually infectious, i.e. cannot transmit HIV through sexual contact.”

Further controversy has erupted in the past year over moves to initiate testing and early HIV treatment in order to lower HIV transmission rates at a citywide level. These programs, called testing and linkage to care and treatment, or TLC+, are being studied in New York City and Washington, DC. In addition, San Francisco’s Department of Health recently took the aggressive step of recommending that all of its HIV-positive residents should start ARV treatment regardless of their CD4 count, in large part to reduce HIV transmission rates in the city.

No one knows, however, to what degree TLC+ will be effective and whether rolling it out might have unintended consequences, including higher rates of side effects and an increase in the number of drug-resistant HIV cases. One trial examining the feasibility of TLC+ is the HIV Prevention Trials Network (HPTN) 065 study. A separate, large-scale controlled trial looking at the effect of ARVs on transmission, HPTN 052, is ongoing, but results are not expected for several years. In the meantime, researchers and advocates have been eagerly awaiting smaller studies on transmission risk between partners.

One such study has now concluded. A team of researchers led by Deborah Donnell, PhD, from the Fred Hutchinson Cancer Research Center in Seattle, studied the effect of treatment on transmission within 3,381 discordant couples in seven African countries. During the six-year study, 349 of the HIV-positive participants started ARV therapy. Of the 103 inter-couple transmissions—those where they could genetically link the strain of HIV from one partner to the other—only one occurred in a couple where the HIV-positive partner was on treatment. Moreover, in the couples where the HIV-positive partner was not on ARVs, high CD4 counts and low viral loads among the partners with HIV also appeared to reduce transmission rates.

“These results are an important finding in the search for effective HIV prevention strategies and the strongest evidence to date that ART might decrease HIV transmission risk,” concluded Connie Celum, MD, from the University of Washington in Seattle, and the paper’s senior author.

Search: TLC+, Swiss Federal Commission, HPTN 052, HPTN 065, Deborah Donnell, Connie Celum, treatment as prevention

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.